 | Up a level |
2022
Simon, C., Lefevre, C. Fortpied, Govaerts, A-S., Raveloarivahy, T., Bourhis, J., Evans, M., Klussmann, J. P., Leemans, C. R., Hunter, K. D., Singer, S., Nuyts, S., Willemse, E., Ansarin, M., Spriano, G., Golusinski, W., Giger, R., Boehm, A., Lopez, F. and Gregoire, V. (2022). Phase III study assessing the best of radiotherapy compared to the best of surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma. Ann. Oncol., 33 (7). S. S865 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2017
Cora, N. S., Sergio, B., Ugo, D. G., Giuseppe, P., Simon, C., Wassim, A., Angel, A. A. Jose, Gedske, D., Karim, F., Eliahu, G., Axel, H., Florence, J., Ray, M., Axel, S. M., Maria, P. Josep, Brieuc, S., Srikala, S., Tony, G., Charles, J. R. and Howard, I. S. (2017). The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041